Sugi Predict

Sugi Predict / Compounds / SCHEMBL1327324

SCHEMBL1327324

SCHEMBL1327324

O=C1[C@@H]2Cc3c([nH]c4ccccc34)[C@H](c3ccc4c(c3)OCO4)N2C(=O)CN1C1CC1

nearest known ligand 0.92

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PDE5A O76074 12/20 0.92
▸ PDE6D O43924 5/20 0.81
▸ PDE6A P16499 5/20 0.81
▸ PDE6G P18545 5/20 0.81
▸ PDE6B P35913 5/20 0.81
▸ PDE6C P51160 5/20 0.81
▸ PDE6H Q13956 5/20 0.81
▸ PDE11A Q9HCR9 7/20 0.78
▸ NR1I2 O75469 1/20 0.78
▸ ACHE P22303 1/20 0.78
▸ PDE4A P27815 1/20 0.78
▸ MAPK1 P28482 1/20 0.78
▸ SLC6A4 P31645 1/20 0.78
▸ PDE4B Q07343 1/20 0.78
▸ PDE4C Q08493 1/20 0.78
▸ PDE4D Q08499 1/20 0.78
▸ KCNH2 Q12809 1/20 0.78
▸ NR2E1 Q9Y466 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1327321 1.00 PDE5A (0.92) PDE5APDE6DPDE6APDE6GPDE6B
SCHEMBL1327318 1.00 PDE5A (0.92) PDE5APDE6DPDE6APDE6GPDE6B
SCHEMBL6782140 0.97 PDE5A (0.98) PDE5APDE6DPDE6APDE6GPDE6B
SCHEMBL6782131 0.97 PDE5A (0.98) PDE5APDE6DPDE6APDE6GPDE6B
SCHEMBL6782137 0.97 PDE5A (0.98) PDE5APDE6DPDE6APDE6GPDE6B
SCHEMBL1327741 0.97 PDE5A (0.98) PDE5APDE6DPDE6APDE6GPDE6B
SCHEMBL7443215 0.96 PDE5A (1.00) PDE5APDE6DPDE6APDE6GPDE6B
SCHEMBL7689513 0.96 PDE5A (1.00) PDE5APDE6DPDE6APDE6GPDE6B
SCHEMBL7689516 0.96 PDE5A (1.00) PDE5APDE6DPDE6APDE6GPDE6B
SCHEMBL17390222 0.95 PDE5A (0.86) PDE5APDE6DPDE6APDE6GPDE6B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6225315-B1 ADMINISTERING A CGMP PDE INHIBITOR. PFIZER INC 2001-05-01 — — US claimed
US-6140329-A FOR TREATING A MALE ANIMAL FOR ERECTILE DYSFUNCTION ICOS CORPORATION (US) 2000-10-31 — — US claimed
EP-1022026-A2 Pharmaceutical compositions for treating nitrate-induced tolerance Pfizer Limited (GB) 2000-07-26 — — EP claimed
US-9943398-B2 Increasing survival of free tissue grafts and flaps using phosphodiesterase type 5 (PDE5) inhibitors NEW YORK UNIVERSITY (US) 2018-04-17 — — US disclosed
US-20140018936-A1 INCREASING SURVIVAL OF FREE TISSUE GRAFTS AND FLAPS USING PHOSPHODIESTERASE TYPE 5 (PDE5) INHIBITORS NEW YORK UNIVERSITY (US) 2014-01-16 — — US disclosed
US-8058305-B2 Pyrrolidine derivatives as prostaglandin modulators MERCK SERONO SA (CH) 2011-11-15 — — US disclosed
EP-2327408-A1 Tetracyclic cyclic gmp-specific phosphodiesterase inhibitors for the treatment of benign prostatic hypertrophy ICOS Corporation (US) 2011-06-01 — — EP disclosed
EP-1458679-B1 PYRROLIDINE DERIVATIVES AS PROSTAGLANDIN MODULATORS MERCK SERONO SA (CH) 2010-01-20 — — EP disclosed
US-20090292000-A1 PYRROLIDINE DERIVATIVES AS PROSTAGLANDIN MODULATORS LABORATOIRES SERONO S.A. (CH) 2009-11-26 — — US disclosed
EP-1331950-B1 EX VIVO METHODS AND COMPOSITIONS FOR NUCLEIC ACID DELIVERY UNIV JOHNS HOPKINS (US) 2009-10-14 — — EP disclosed
EP-2036560-A1 (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione for the treatment of benign prostatic hypertrophy ICOS Corporation (US) 2009-03-18 — — EP disclosed
US-20020094326-A1 Methods and compositions for nucleic acid delivery JOHNS HOPKINS UNIVERSITY 2002-07-18 — — US disclosed
US-6369059-B1 INHIBITOR OF CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE SPECIFIC PHOSPHODIESTERASE (CGMP SPECIFIC PDE); CARDIOVASCULAR DISORDERS; PYRAZINO(2',1':6,1)PYRIDO(3,4-B)INDOLE-1,4-DIONES ICOS CORPORATION 2002-04-09 — — US disclosed
US-20020035111-A1 Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B] indole derivatives OSI PHARMACEUTICALS, INC. 2002-03-21 — — US disclosed
US-6225315-B1 ADMINISTERING A CGMP PDE INHIBITOR. PFIZER INC 2001-05-01 — — US disclosed
US-6140329-A FOR TREATING A MALE ANIMAL FOR ERECTILE DYSFUNCTION ICOS CORPORATION (US) 2000-10-31 — — US disclosed
EP-1022026-A2 Pharmaceutical compositions for treating nitrate-induced tolerance Pfizer Limited (GB) 2000-07-26 — — EP disclosed
EP-0740668-B1 TETRACYCLIC DERIVATIVES, PROCESS OF PREPARATION AND USE ICOS CORP (US) 1998-07-29 — — EP disclosed
EP-0839040-A1 USE OF CGMP-PHOSPHODIESTERASE INHIBITORS TO TREAT IMPOTENCE ICOS CORPORATION (US) 1998-05-06 — — EP disclosed
WO-1997003675-A1 USE OF CGMP-PHOSPHODIESTERASE INHIBITORS TO TREAT IMPOTENCE ICOS CORPORATION (US) 1997-02-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020035111-A1 Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B] indole derivatives MKI67, PNPO, CDK4 PDE5A 4371/4885PDE6D 4733/4885PDE6A 4705/4885
US-20090292000-A1 PYRROLIDINE DERIVATIVES AS PROSTAGLANDIN MODULATORS PGF, PTGIS, PDE5A PDE5A 3/4885PDE6D 187/4885PDE6A 74/4885
US-20020094326-A1 Methods and compositions for nucleic acid delivery TNNC1, TNNI3, TNNT2 PDE5A 2130/4885PDE6D 1389/4885PDE6A 1004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.